Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synergen's SLPI

Executive Summary

Company's natural elastase inhibitor designated an orphan product by FDA. The enzyme is being developed as a treatment for cystic fibrosis and genetic emphysema. Phase II trials are expected to begin later this year .... Antril: Synergen begins Phase II studies of the recombinant interleukin-1 receptor agonist in patients with sepsis and septic shock. The Boulder, Colorado- based biotech firm hopes to enroll 100 patients over the next six months.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS019129

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel